The purpose of the present study was to evaluate the pharmacokinetic interaction of vitexin rhamnoside (vitexin 2''-α-Lrhamnopyranosyl) and vitexin glucoside (vitexin 2''-β-D-glucopyranosyl) in rats by using a high performance liquid chromatography coupled with tandem mass spectrometry quantitative detection method (LC-MS/MS). The method was validated at the concentration range of 5 -5000 ng/mL for both vitexin rhamnoside and vitexin glucoside with the regression equations Y = 0.00181X -0.000955 (r > 0.998) and Y = 0.000788X -0.000373 (r > 0.997), respectively. The methodological studies (including linearity, intra-assay / inter-assay accuracy and precision) of these two components were investigated. The pharmacokinetic parameters of these two components were compared, which demonstrated their pharmacokinetic variance, especially when they were administrated simultaneously.
Hawthorn, a traditional Chinese medicine (TCM), is prepared from the dried fruits and leaves of either Crataegus pinnatifida Bge. var. major N. E. Br. or Crataegus pinnatifida (Rosaceae) [1] . It is currently utilized for the treatment of heart failure, such as reducing cholesterol and lipoprotein of experimental hyperlipemia [2, 3] , treating experimental atherosclerosis [4, 5] , increasing blood flow in the coronary artery [6] , resisting myocardial ischemia [7, 8] , and reducing blood pressure [9] . Now it is widely used in America and Europe for the commercial production of pharmaceuticals with cardiotonic, coronary vascodilatoric and hypotensive action [5, 10] .
The chemical composition of hawthorn includes flavonoids, pentacyclic triterpenoid acids, phenolic acids and proanthocyanidins [11] [12] [13] . As reported previously, flavonoids were considered as the main bioactive constituents in hawthorn for the treatment of atherosclerosis, myocardial ischemia and hypertension [7, [14] [15] [16] . Among these compounds, vitexin rhamnoside and vitexin glucoside were considered to be the most important, with the content of vitexin rhamnoside being over 2%. Our pharmacological studies demonstrated that these two compounds possess various pharmacological effects on the cardiovascular system and that there is an urgent need to study their pharmacokinetics in vivo [17] .
The amount of flavonoids accumulated in raw materials is a parameter of quality. As reported previously, flavonoids can be analyzed by gas chromatography (GC) [18, 19] , high performance liquid chromatography-ultraviolet (HPLC-UV) [11, 20] , liquid chromatography-mass spectrometry (LC-MS) [17, 21] , capillary zone electrophoresis (CZE) [22] , and micellar electrokinetic capillary chromatography (MEKC) [23, 24] . The quality control of hawthorn fruit and leaves is also defined in the China Pharmacopoeia (vol. 1, Version 2005), in which flavonoids are identified and determined by TLC and HPLC methods, but no analytical method for vitexin rhamnoside is required [1] .
The pharmacokinetic study of the interaction of hawthorn extract and digoxin in vivo revealed that hawthorn extract had no significant influence on the measured pharmacokinetic parameters of digoxin, which indicated that these two drugs might be co-administered safely [25] . The pharmacokinetics of hawthorn phenolics in hawthorn extracts were also studied to show possible pharmacokinetic differences in two formulations following intravenous administration and potentially alter the pharmacokinetics of these ingredients [26] . There have been no studies of the interaction of hawthorn flavonoids in vivo. This current study describes a rapid, selective and sensitive liquid chromatographic technique coupled with tandem mass spectrometry (LC-MS/MS) for the determination of vitexin rhamnoside and vitexin glucoside in plasma, and the pilot pharmacokinetic studies of these two components were characterized after intravenous injection singly and in combination. By using this established LC-MS/MS method, we evaluated, in detail, the in vivo pharmacokinetic interaction of these two hawthorn flavonoids to show the complexity of TCM during clinical applications.
LC-MS/MS characteristics:
With a mobile phase of methanol, water and acetonitrile (50:45:5), the retention time was 1.17 min for vitexin rhamnoside, 1.14 min for vitexin glucoside, and 1.04 min for aesculin. Under the proposed LC-MS/MS conditions, the investigated substances were detected without any interference from the blank rat plasma (Figure 1) .
Linearity:
The LC-MS/MS-based method described in this report has high sensitivity and specificity. The standard curve obtained from the analysis of plasma containing known amounts of vitexin rhamnoside was linear from 5 to 5000 ng/mL in 0.1 mL rat plasma, as was vitexin glucoside. The calibration curves of vitexin rhamnoside were linear and could be described by the regression equation Y = 0.00181X -0.000955 with a correlation coefficient of over 0.998; for vitexin glucoside, the calibration curve equation was Y = 0.000788X-0.000373, with a correlation coefficient of over 0.997. Both of the LLOQ (lowest limit of quantitation) values were 5 ng/mL in 0.1 mL rat plasma. This sensitivity has proven useful in the analysis of pharmacokinetic data from rats treated intravenously. 
Sample stability analysis:
The results of the intraand inter-day assays are listed in Tables 1 and 2 . The accepted criteria for each quality control were that the deviation values of precision and accuracy should not exceed 15%. The values suggested that the procedure described above was satisfactory for both vitexin rhamnoside and vitexin glucoside.
After three freeze-thaw cycles of the investigated plasma samples, the three concentrations (8 ng/mL, 800 ng/mL and 4000 ng/mL for both components) were not significantly different from those of the freshly prepared vitexin rhamnoside and vitexin glucoside. The three concentrations also proved to be stable at room temperature for 4 h and at -20ºC for 20 days, with the coefficients of variation less than 10%. 
Pharmacokinetic comparisons:
Following intravenous administration of each component and the combination of the two components, plasma drug concentration-time profiles were plotted as shown in Figure 2 . The pharmacokinetic parameter values are summarized in Table 3 . The method was further applied to compare the pharmacokinetics of each single component and the combination of the two components in rats. The results demonstrated pharmacokinetic variance of vitexin rhamnoside and vitexin glucoside, especially when they were administrated simultaneously. From the P values of the T-test statistical analysis shown in Table 3 , it was concluded that the AUC (area under the curve) of single component administration was higher than that of combination administration for both components. Also, the clearance after single component administration was lower than that of combination administration for both components. However, it is interesting that the change of the half-life (T ½ ) is not identical for the two components. For vitexin rhamnoside, the half-life after single component administration was longer than that of combination administration, while for vitexin glucoside, the halflife after single component application was shorter than that of combination administration.
We have developed a simple and accurate analytical LC-MS/MS method for simultaneous determination of vitexin rhamnoside and vitexin glucoside in rat T ime (Hour)
Conc (ng/mL)
Si ngl e com ponent In order to compare the in vivo pharmacokinetics of single component and combination administration of the two components after intravenous administration, 12 rats were randomly divided into 3 groups. The first group was dosed with vitexin rhamnoside, the second with vitexin glucoside, and the third with the combination of these two components. Vitexin rhamnoside and vitexin glucoside were dissolved in saline and the injection volume was adjusted to 0.1 mL/100g by intravenous administration. The dose was 10 mg/Kg for each component when administrated either separately or when in combination. Blood samples (0.3 mL) were withdrawn from the carotid vein by carotid cannulation at 0, 5, 10, 15, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0 and 6.0 h after intravenous administration, and placed in heparinized tubes. The plasma samples were centrifuged at 3000 g for 5 min and stored at -20°C until analysis.
Standard and sample preparation:
A stock mixture solution of vitexin rhamnoside and vitexin glucoside was prepared by dissolving the drugs in methanol to a final concentration of 200 μg/mL for each component. The mixture solution was diluted to a series of working solutions at concentrations of 25, 50, 250, 500, 2500, 5000, 10000 and 25000 ng/mL. From each working solution, 20 μL was placed in a glass tube, and the solvent evaporated under a compressed air stream. The dried analyte was reconstituted using 100 μL blank plasma to yield final concentrations of 5, 10, 50, 100, 500, 1000, 2000 and 5000 ng/mL in plasma. Three quality control solutions at concentrations of 8, 800 and 4000 ng/mL were also prepared in blank plasma. A 200 μg/mL stock solution of aesculin (IS) in methanol was prepared. This solution was diluted with methanol to a final concentration of 50 ng/mL.
The plasma sample (100 μL) was precipitated using 300 μL IS solution. After the mixture had been stirred for 1.0 min, and centrifuged at 3000 g for 5 min, 5 μL of the supernatant was injected into the LC-MS/MS system for analysis.
LC-MS/MS conditions:
An Agilent 1100 HPLC system (Agilent Inc, MA, USA) was used, which consisted of a quaternary pump, an autosampler, a degasser, an automatic thermostatic column compartment and a computer with Chemstation software (Analyst 1.4, Applied Biosystems Inc., USA). The analytical column used was a Luna reversed-phase analytical column (5μm, 100 × 2.0 mm, Phenomenex) and a SB-C 18 guard column (5 μm, 20 × 4.0 mm). A mixture of methanol, water and acetonitrile in the ratio 50:45:5 was used as the mobile phase. The column was equilibrated and eluted under isocratic conditions with a flow rate of 300 uL/min. The column temperature was set at 25°C.
A triple quadrupole mass spectrometer (API3000, ABI., USA) was used, with a TurboIonSpray ion source, which was connected to the liquid chromatography system. High-purity nitrogen was provided by a liquid nitrogen tank. The conditions for mass spectrometry were set at negative MRM mode on the parent and product ion of three components (m/z: vitexin rhamnoside at 577. 
Method validation:
The calibration curves were constructed using seven non-zero standards ranging from 5 to 5000 ng/mL and prepared on five separate days. A blank sample (matrix sample processed without internal standard) was used to exclude contamination. The linear regression analysis was performed by plotting the peak area ratio (y) against the analyte concentration (x) in ng/mL. The linearity of the relationship between peak area ratio and concentration was demonstrated by the correlation coefficients (R). The relative standard deviation (RSD) was calculated for all the non-zero standards and compared to the nominal values.
Intra-day and inter-day variations in the assay method were evaluated by quintuplicate analyses of three quality control samples. The calibration standards and quality controls were analyzed on five different days in order to determine intra-day and inter-day precision and accuracy.
Three QC samples were determined before and after one freeze-thaw cycle to evaluate the freeze-thaw stability. The long-term freeze stability was also evaluated by storing the samples at -20 o C for 20 days. The stability at room temperature was assessed by maintaining the QC samples at room temperature for 4 h. where C n is the concentration of the last sampling, and λ n is the elimination rate constant.
T-test statistical analysis was applied to evaluate whether there were significant differences between the pharmacokinetic behavior of each component (vitexin rhamnoside or vitexin glucoside) versus their combination.
